In the original article, we neglected to include the funder. This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 713714 to Reyes Dominguez-Benot.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
theranostic nanoplatform, brain tumors, targeted therapy, drug delivery, diagnosis
Citation
d'Angelo M, Castelli V, Benedetti E, Antonosante A, Catanesi M, Dominguez-Benot R, Pitari G, Ippoliti R and Cimini A (2020) Corrigendum: Theranostic Nanomedicine for Malignant Gliomas. Front. Bioeng. Biotechnol. 7:468. doi: 10.3389/fbioe.2019.00468
Received
19 December 2019
Accepted
20 December 2019
Published
30 January 2020
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
7 - 2019
Updates
Copyright
© 2020 d'Angelo, Castelli, Benedetti, Antonosante, Catanesi, Dominguez-Benot, Pitari, Ippoliti and Cimini.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Annamaria Cimini annamaria.cimini@univaq.it
This article was submitted to Nanobiotechnology, a section of the journal Frontiers in Bioengineering and Biotechnology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.